ACBD4: A Protein Involved in Energy Homeostasis and Disease (G79777)

Target Name: ACBD4

NCBI ID: G79777

ACBD4

ACBD4: A Protein Involved in Energy Homeostasis and Disease

ACBD4, or Acyl-CoA binding domain containing 4, is a protein that is expressed in various tissues and cells throughout the body. It is a key component of the acyl-coa synthetase complex, a protein complex that is involved in the production of fatty acids from acetyl-CoA (acetyl-CoA). This complex is critical for maintaining cellular energy homeostasis and has been implicated in a wide range of biological processes, including metabolism, inflammation, and aging.

In recent years, researchers have become increasingly interested in ACBD4 as a potential drug target or biomarker. This is because the ACBD4 protein has been shown to play a role in a variety of diseases and conditions, including obesity, type 2 diabetes, and certain forms of cancer. In addition, studies have suggested that inhibiting ACBD4 activity may be a promising approach for treating these conditions.

One of the key reasons for the interest in ACBD4 as a drug target is its role in obesity. Obesity, which is defined as a body mass index (BMI) of 25 or greater, is a major public health issue that is associated with a range of negative health consequences, including increased risk of cardiovascular disease, diabetes, and certain cancers. Many of these conditions are caused or exacerbated by the imbalance of energy in the body, and ACBD4 has been shown to be involved in this process.

For example, studies have shown that ACBD4 is highly expressed in obese individuals and that inhibiting its activity may be an effective way to reduce body weight. In addition, research has suggested that ACBD4 may be involved in the production of intracellular fat, which can contribute to obesity.

Another potential application of ACBD4 as a drug target is its role in type 2 diabetes. This disease, which is a chronic condition that is characterized by high levels of blood sugar, is a major cause of morbidity and mortality around the world. In addition, research has suggested that ACBD4 may be involved in the production of insulin, which is a hormone that helps regulate blood sugar levels. In some cases, ACBD4 has been shown to be expressed in individuals with type 2 diabetes and that inhibiting its activity may be a promising approach for treating this disease.

Finally, ACBD4 has also been shown to be involved in the production of certain forms of cancer. For example, studies have shown that ACBD4 is highly expressed in a variety of cancer cells and that inhibiting its activity may be an effective way to treat these diseases . In addition, research has suggested that ACBD4 may be involved in the production of pro-inflammatory compounds, which can contribute to the development and progression of certain cancers.

In conclusion, ACBD4 is a protein that is involved in a wide range of biological processes and has been implicated in a variety of diseases and conditions. As a result, it has generated a great deal of interest as a potential drug target or biomarker. Further research is needed to fully understand the role of ACBD4 in these processes and to determine the most effective way to inhibit its activity. However, the potential benefits of ACBD4 as a drug or biomarker are significant and continue to be an area of 鈥嬧?媋ctive research.

Protein Name: Acyl-CoA Binding Domain Containing 4

Functions: Binds medium- and long-chain acyl-CoA esters and may function as an intracellular carrier of acyl-CoA esters

The "ACBD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACBD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets